drugset / Trial / NCT06019741

Rivaroxaban Post Coronary Bypass Surgery

NCT06019741

Phase 4 Completed 234 enrolled Shiraz University of Medical Sciences
RandomizedParallel-groupQuadruple-blindTreatment

Summary

Post coronary bypass patients were randomized to receiving aspirin alone or aspirin and low dose rivaroxaban

Timeline

Start
2021-02-01
Primary completion
2022-05-01
Completion
2022-07-20

Drugs

EvaluationDrugModalityDoseRoute
Subject Rivaroxaban Other / unclassified 2.5 mg Oral
Comparator Aspirin Small molecule 80 mg Oral